BioSpace News Archive

NanoString Technologies, Inc. announced that the Company will report first quarter 2022 operating results after the close of the market on Tuesday, May 10, 2022.

Sio Gene Therapies Inc. announced that it has provided the required notice to the University of Massachusetts to terminate its licensing agreement to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM2, for the treatment of GM1 gangliosidosis and GM2 gangliosidosis, respectively.

ICON plc, a world-leading healthcare intelligence and clinical research organisation, reported its financial results for the first quarter ended March 31, 2022.

Oncocyte Corporation announced that it plans to present new data from ongoing clinical research evaluating the utility of DetermaIO™ at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 3-7, 2022 virtually and in-person in Chicago.

Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, announced the presentation of four poster presentations during the Florida Society of Dermatology Physician Assistants 2022 New Wave Dermatology Conference, which will take place in Coral Gables, Fla. from April 28 - May 1, 2022.

Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter ended March 31, 2022.

Petros Pharmaceuticals, Inc., a leading provider of therapeutics for men’s health, announces that President and Chief Commercial Officer Fady Boctor will present virtually at the Planet MicroCap Showcase 2022.

Calliditas Therapeutics AB announces that the Annual Report for 2021 now is available at the company’s website.

According to Report, the global biomarkers market is estimated to reach valuation US$ 150.59 billion by 2030 and is expected to grow at a CAGR of 16.2% during forecast period 2021 to 2030.